File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience

TitleAllogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience
Authors
Issue Date2013
PublisherCognizant Communication Corp. The Journal's web site is located at https://www.cognizantcommunication.com/journal-titles/cell-transplantation
Citation
Cell Transplantation, 2013, v. 22 n. 12, p. 2267-2277 How to Cite?
AbstractMesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitors and are capable of differentiating into several tissues of mesenchymal origin. We have shown that bone marrow-derived MSCs from both SLE patients and lupus-prone MRL/lpr mice are defective structurally and functionally. Here we observe the long-term safety and efficacy of allogeneic MSC transplantation (MSCT) in treatment-resistant SLE patients. Eighty-seven patients with persistently active SLE who were refractory to standard treatment or had life-threatening visceral involvement were enrolled. Allogeneic bone marrow or umbilical cord-derived MSCs were harvested and infused intravenously (1 × 10(6) cells/kg of body weight). Primary outcomes were rates of survival, disease remission and relapse, as well as transplantation-related adverse events. Secondary outcomes included SLE disease activity index (SLEDAI) and serologic features. During the 4-year follow-up and with a mean follow-up period of 27 months, the overall rate of survival was 94% (82/87). Complete clinical remission rate was 28% at 1 year (23/83), 31% at 2 years (12/39), 42% at 3 years (5/12), and 50% at 4 years (3/6). Rates of relapse were 12% (10/83) at 1 year, 18% (7/39) at 2 years, 17% (2/12) at 3 years, and 17% (1/6) at 4 years. The overall rate of relapse was 23% (20/87). Disease activity declined as revealed by significant changes in the SLEDAI score, levels of serum autoantibodies, albumin, and complements. A total of five patients (6%) died after MSCT from non-treatment-related events in the 4-year follow-up, and no transplantation-related adverse event was observed. Allogeneic MSCT resulted in the induction of clinical remission and improvement in organ dysfunction in drug-resistant SLE patients.
Persistent Identifierhttp://hdl.handle.net/10722/212116
ISSN
2015 Impact Factor: 3.427
2015 SCImago Journal Rankings: 1.161

 

DC FieldValueLanguage
dc.contributor.authorWang, D-
dc.contributor.authorZhang, H-
dc.contributor.authorLiang, J-
dc.contributor.authorLi, X-
dc.contributor.authorFeng, X-
dc.contributor.authorWang, H-
dc.contributor.authorHua, B-
dc.contributor.authorLiu, B-
dc.contributor.authorLu, L-
dc.contributor.authorGilkeson, GS-
dc.contributor.authorSilver, RM-
dc.contributor.authorChen, W-
dc.contributor.authorShi, S-
dc.contributor.authorSun, L-
dc.date.accessioned2015-07-21T02:23:32Z-
dc.date.available2015-07-21T02:23:32Z-
dc.date.issued2013-
dc.identifier.citationCell Transplantation, 2013, v. 22 n. 12, p. 2267-2277-
dc.identifier.issn0963-6897-
dc.identifier.urihttp://hdl.handle.net/10722/212116-
dc.description.abstractMesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitors and are capable of differentiating into several tissues of mesenchymal origin. We have shown that bone marrow-derived MSCs from both SLE patients and lupus-prone MRL/lpr mice are defective structurally and functionally. Here we observe the long-term safety and efficacy of allogeneic MSC transplantation (MSCT) in treatment-resistant SLE patients. Eighty-seven patients with persistently active SLE who were refractory to standard treatment or had life-threatening visceral involvement were enrolled. Allogeneic bone marrow or umbilical cord-derived MSCs were harvested and infused intravenously (1 × 10(6) cells/kg of body weight). Primary outcomes were rates of survival, disease remission and relapse, as well as transplantation-related adverse events. Secondary outcomes included SLE disease activity index (SLEDAI) and serologic features. During the 4-year follow-up and with a mean follow-up period of 27 months, the overall rate of survival was 94% (82/87). Complete clinical remission rate was 28% at 1 year (23/83), 31% at 2 years (12/39), 42% at 3 years (5/12), and 50% at 4 years (3/6). Rates of relapse were 12% (10/83) at 1 year, 18% (7/39) at 2 years, 17% (2/12) at 3 years, and 17% (1/6) at 4 years. The overall rate of relapse was 23% (20/87). Disease activity declined as revealed by significant changes in the SLEDAI score, levels of serum autoantibodies, albumin, and complements. A total of five patients (6%) died after MSCT from non-treatment-related events in the 4-year follow-up, and no transplantation-related adverse event was observed. Allogeneic MSCT resulted in the induction of clinical remission and improvement in organ dysfunction in drug-resistant SLE patients.-
dc.languageeng-
dc.publisherCognizant Communication Corp. The Journal's web site is located at https://www.cognizantcommunication.com/journal-titles/cell-transplantation-
dc.relation.ispartofCell Transplantation-
dc.rightsCell Transplantation. Copyright © Cognizant Communication Corp.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleAllogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience-
dc.typeArticle-
dc.identifier.emailLu, L: liweilu@hkucc.hku.hk-
dc.identifier.authorityLu, L=rp00477-
dc.description.naturepublished_or_final_version-
dc.identifier.pmid24388428-
dc.identifier.hkuros244999-
dc.identifier.volume22-
dc.identifier.issue12-
dc.identifier.spage2267-
dc.identifier.epage2277-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats